Literature DB >> 1964818

Negative inotropic effects of disopyramide on guinea-pig papillary muscles.

N Kondo1, M Mizukami, S Shibata.   

Abstract

1. The inhibitory effects of disopyramide on electromechanical responses were investigated in guinea-pig papillary muscles driven by electrical stimuli. Disopyramide up to 10(-5) M did not cause a negative inotropic effect, while the maximum upstroke velocity of the action potential (dV/dtmax) was significantly decreased. 2. At higher concentrations, this drug dose-dependently inhibited the contraction, and dV/dtmax was further decreased. This inhibition of contraction was accompanied by a depression of the slow action potential in partially depolarized preparations by increasing [K+]0 (26 mM). 3. In preparations pretreated with nifedipine (10(-6) M) and ryanodine (10(-6) M), the contraction was almost completely inhibited. In such preparations, ouabain (2 x 10(-6) M) markedly increased the contraction, probably through the Na(+)-Ca2+ exchange mechanism. This contraction was inhibited by disopyramide above 10(-8) M, and an almost complete inhibition was caused at 3 x 10(-5) M. 4. A similar inhibitory effect was observed on the contraction increased by the lowering of [Na+]0 (36 mM). 5. These results suggest that disopyramide at high concentrations inhibits Ca influx through slow Ca2+ channels and at low concentrations, it reduces the contraction increased through the Na(+)-Ca2+ exchange mechanism. Disopyramide had a greater effect on cardiac contractility mediated by the Na(+)-Ca2+ exchange mechanism.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964818      PMCID: PMC1917854          DOI: 10.1111/j.1476-5381.1990.tb14158.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  The pharmacology of disopyramide.

Authors:  W G Nayler
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

2.  Circulatory effects of intravenous disopyramide in heart failure.

Authors:  G Jensen; A Uhrenholt
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

3.  Some aspects of the clinical pharmacology of intravenous disopyramide after myocardial infarction.

Authors:  W S Hillis; A Tweddel; A R Lorimer; T D Lawrie
Journal:  J Int Med Res       Date:  1976       Impact factor: 1.671

Review 4.  Excitation-contraction coupling in cardiac muscle.

Authors:  R A Chapman
Journal:  Prog Biophys Mol Biol       Date:  1979       Impact factor: 3.667

5.  The dependence of calcium efflux from cardiac muscle on temperature and external ion composition.

Authors:  H Reuter; N Seitz
Journal:  J Physiol       Date:  1968-03       Impact factor: 5.182

6.  Adverse hemodynamic effects of intravenous disopyramide compared with quinidine in conscious dogs.

Authors:  R A Walsh; L D Horwitz
Journal:  Circulation       Date:  1979-11       Impact factor: 29.690

7.  Haemodynamic effects of disopyramide in patients after open-heart surgery.

Authors:  N Naqvi; D S Thompson; W E Morgan; B T Williams; D J Coltart
Journal:  Br Heart J       Date:  1979-11

8.  Haemodynamic and electrocardiographic effects of intravenous disopyramide (rythmodan) following acute myocardial infarction.

Authors:  G J Davies; P K Marrott; J R Muir
Journal:  Br J Clin Pharmacol       Date:  1979-02       Impact factor: 4.335

9.  Kinetics of hemodynamic and electrocardiographic changes following intravenous disopyramide.

Authors:  J Hulting; G Rosenhamer
Journal:  Acta Med Scand       Date:  1979

10.  Excitation-contraction coupling in cardiac Purkinje fibers. Effects of cardiotonic steroids on the intracellular [Ca2+] transient, membrane potential, and contraction.

Authors:  W G Wier; P Hess
Journal:  J Gen Physiol       Date:  1984-03       Impact factor: 4.086

View more
  1 in total

Review 1.  Targets for therapy in sarcomeric cardiomyopathies.

Authors:  Jil C Tardiff; Lucie Carrier; Donald M Bers; Corrado Poggesi; Cecilia Ferrantini; Raffaele Coppini; Lars S Maier; Houman Ashrafian; Sabine Huke; Jolanda van der Velden
Journal:  Cardiovasc Res       Date:  2015-01-29       Impact factor: 10.787

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.